These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 22475391)

  • 21. Levodopa induced motor complications in Thai Parkinson's disease patients.
    Kulkantrakorn K; Tiamkao S; Pongchaiyakul C; Pulkes T
    J Med Assoc Thai; 2006 May; 89(5):632-7. PubMed ID: 16756048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of dopamine receptor agonists in the treatment of early Parkinson's disease.
    Bonuccelli U; Del Dotto P; Rascol O
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S44-53. PubMed ID: 20123557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment in early Parkinson's disease: the Norwegian ParkWest study.
    Tveiten OV; Skeie GO; Haugarvoll K; Müller B; Larsen JP; Tysnes OB
    Acta Neurol Scand; 2013 Aug; 128(2):107-13. PubMed ID: 23190324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parkinson's disease: health-related quality of life, economic cost, and implications of early treatment.
    Chen JJ
    Am J Manag Care; 2010 Mar; 16 Suppl Implications():S87-93. PubMed ID: 20297871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease.
    Zibetti M; Rizzone M; Merola A; Angrisano S; Rizzi L; Montanaro E; Cicolin A; Lopiano L
    Acta Neurol Scand; 2013 May; 127(5):e28-32. PubMed ID: 23311399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New non-oral drug delivery systems for Parkinson's disease treatment.
    Md S; Haque S; Sahni JK; Baboota S; Ali J
    Expert Opin Drug Deliv; 2011 Mar; 8(3):359-74. PubMed ID: 21314492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levodopa in Parkinson's disease: from the past to the future.
    Pezzoli G; Zini M
    Expert Opin Pharmacother; 2010 Mar; 11(4):627-35. PubMed ID: 20163273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How should we treat a patient with early Parkinson's disease?
    Tsouli S; Konitsiotis S
    Int J Clin Pract; 2010 Aug; 64(9):1210-9. PubMed ID: 20653797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safinamide for the treatment of Parkinson's disease.
    Dézsi L; Vécsei L
    Expert Opin Investig Drugs; 2014 May; 23(5):729-42. PubMed ID: 24650154
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Implication of piribedil (pronoran) in the treatment of Parkinson's disease; a clinical and pharmacoeconomic analysis].
    Mil'chakova AE; Popov GR; Bykov AV; Gekht AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):49-55. PubMed ID: 18567194
    [No Abstract]   [Full Text] [Related]  

  • 32. Impact of Parkinson's disease and its pharmacologic treatment on quality of life and economic outcomes.
    Scheife RT; Schumock GT; Burstein A; Gottwald MD; Luer MS
    Am J Health Syst Pharm; 2000 May; 57(10):953-62. PubMed ID: 10832495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rational drug discovery design approaches for treating Parkinson's disease.
    Van der Schyf CJ
    Expert Opin Drug Discov; 2015 Jul; 10(7):713-41. PubMed ID: 26054694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Review of the economic evidence on the use of deep brain stimulation in late stage Parkinson's disease].
    Puig-Junoy J; Puig Peiró R
    Neurologia; 2009 May; 24(4):220-9. PubMed ID: 19603291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pharmacoeconomic study of the treatment of advanced Parkinson's disease].
    Vivancos-Matellano F; Garcia-Ruiz AJ; Garcia-Agua Soler N
    Rev Neurol; 2016 Dec; 63(12):529-536. PubMed ID: 27897303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parkinson's disease: a long and difficult journey.
    Casey G
    Nurs N Z; 2013 Aug; 19(7):20-4. PubMed ID: 24195263
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modelling the cost effectiveness of treatments for Parkinson's disease: a methodological review.
    Dams J; Bornschein B; Reese JP; Conrads-Frank A; Oertel WH; Siebert U; Dodel R
    Pharmacoeconomics; 2011 Dec; 29(12):1025-49. PubMed ID: 22077577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parkinson's disease, antiparkinson medicines, and driving.
    Álvarez FJ
    Expert Rev Neurother; 2016 Sep; 16(9):1023-32. PubMed ID: 27464001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The incorporation of potential confounding variables in Markov models.
    Nuijten MJ; Rutten F
    Pharmacoeconomics; 2003; 21(13):941-50. PubMed ID: 12959626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of decision-analytic models in Parkinson's disease: a systematic review and critical appraisal.
    Shearer J; Green C; Counsell CE; Zajicek JP
    Appl Health Econ Health Policy; 2011 Jul; 9(4):243-58. PubMed ID: 21682352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.